Quote: …biib will be a better [FoB] partner [for MNTA] than Sandoz. I disagree. When Wheeler spoke on the GS webcast of companies who “cannot get out of their own way in protecting their legacy businesses,” I immediately thought of BIIB. It is presumably one of the companies where executives worry unduly that their branded biologics could eventually be cannibalized by MNTA’s biogenerics.
BIIB has also stated that they themselves would need a sales/marketing partner for their FOB efforts. So I don't see MNTA partnering with someone who has the manufacturing, but not the other requisite capabilities.
Market Data 
Markets 
AI
